ClinicalTrials.gg

Program

tofersen

Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Biogen.

Furthest: phase 4, since Oct 31, 20255 company-led studies, 2 open or runningNext primary completion: May 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen52 open or runningphase 4since Oct 31, 2025Nov 24, 2015May 26, 2027phase 4 · NCT07223723

Also a collaborator on its studies: Ionis Pharmaceuticals.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2015First study: phase 3 study in Amyotrophic Lateral SclerosisFirst studyNCT02623699 · 176 enrolled · United States, Australia, Belgium and more
  2. Feb 28, 2017Phase 3 study in ALS Caused by Superoxide Dismutase 1 (SOD1) MutationNCT03070119 · 139 enrolled · United States, Belgium, Canada and more
  3. Dec 3, 2018Phase 1 study in Healthy VolunteersNCT03764488 · 8 enrolled · United States
  4. Apr 20, 2021Phase 3 study in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982 · 158 enrolled · United States, Australia, Belgium and more
  5. Oct 31, 2025Phase 4 study in Amyotrophic Lateral SclerosisNCT07223723 · 12 enrolled · China

Ahead

  1. May 26, 2027Primary completion: phase 4 study in Amyotrophic Lateral SclerosisNCT07223723
  2. Aug 7, 2027Primary completion: phase 3 study in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223723Amyotrophic Lateral Sclerosis · China4Active, not recruitingMay 26, 202712
NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation · United States, Australia, Belgium and more3Active, not recruitingAug 7, 2027158
NCT03764488Healthy Volunteers · United States1CompletedJun 10, 20218
NCT03070119ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation · United States, Belgium, Canada and more3CompletedAug 12, 2024139
NCT02623699Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more3CompletedJul 16, 2021176

How it is read

Names in the registry

  • “Tofersen”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.